Expression of p53 and markers for apoptosis in breast tissue during long-term hormone therapy in cynomolgus monkeys

American Journal of Obstetrics and Gynecology

Volumn 193, Issue 1, 2005, Pages 58-63

  Conner, Peter ^a   Register, Tom C ^b   Skoog, Lambert ^a   Tani, Edneia ^a   Von Schoultz, Bo ^a   Cline, J Mark ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Breast; Cynomolgus macaques; Hormone therapy; p53

Indexed keywords

CASPASE 3; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; PROTEIN P21; PROTEIN P53; TIBOLONE;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MACACA; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; CASPASE 3; CASPASES; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HORMONE REPLACEMENT THERAPY; IMMUNOHISTOCHEMISTRY; MACACA FASCICULARIS; MAMMARY GLANDS, ANIMAL; MEDROXYPROGESTERONE 17-ACETATE; NORPREGNENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 22244432847     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2004.11.056     Document Type: Article

References (27)

1. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, and M.L. Stefanick Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
2. V. Beral Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 2003 419 427
3. R.J. Santen, J. Pinkerton, C. McCartney, and G.R. Petroni Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy J Clin Endocrinol Metab 86 2001 16 23
4. L.K. Weiss, R.T. Burkman, K.L. Cushing-Haugen, L.F. Voigt, M.S. Simon, and J.R. Daling Hormone replacement therapy regimens and breast cancer risk Obstet Gynecol 100 2002 1148 1158
5. J.M. Cline, G. Söderqvist, E. von Schoultz, L. Skoog, and B. von Schoultz Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques Am J Obstet Gynecol 174 1996 93 100
6. J.M. Cline, G. Söderqvist, E. von Schoultz, L. Skoog, and B. von Schoultz Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques Breast Cancer Res Treat 48 1998 221 229
7. P. Conner, G. Söderqvist, L. Skoog, T. Gräser, E. Tani, and K. Carlström Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology Breast Cancer Res Treat 78 2003 159 165
8. P. Conner, A. Christow, W. Kersemaekers, G. Söderqvist, L. Skoog, and K. Carlström A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolone and continuous combined estrogen-progestogen treatment Climacteric 7 2004 50 58
9. E. Lundström, B. Wilczek, Z. von Palffy, G. Söderqvist, and B. von Schoultz Mammographic breast density during hormone replacement therapy: differences according to treatment Am J Obstet Gynecol 181 1999 348 352
10. G.A. Greendale, B.A. Reboussin, A. Sie, H.R. Singh, L.K. Olson, and O. Gatewood Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators Ann Intern Med 130 1999 262 269
11. R.A. Moore Livial: a review of clinical studies BJOG 106 Suppl. 19 1999 1 21
12. M.E. de Gooyer, G.H. Deckers, W.G. Schoonen, H.A. Verheul, and H.J. Kloosterboer Receptor profiling and endocrine interactions of tibolone Steroids 68 2003 21 30
13. E. Lundström, A. Christow, W. Kersemaekers, G. Svane, E. Azavedo, and G. Soderqvist Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density Am J Obstet Gynecol 186 2002 717 722
14. S. Preston-Martin, M.C. Pike, R.K. Ross, P.A. Jones, and B.E. Henderson Increased cell division as a cause of human cancer Cancer Res 50 1990 7415 7421
15. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
16. D. Sidransky, and M. Hollstein Clinical implications of the p53 gene Annu Rev Med 47 1996 285 301
17. D.P. Lane Cancer. p53, guardian of the genome Nature 358 1992 15 16
18. P.B. Rajan, D.J. Scott, R.H. Perry, and C.D. Griffith p53 protein expression in ductal carcinoma in situ (DCIS) of the breast Breast Cancer Res Treat 42 1997 283 290
19. U. Fischer, R.U. Janicke, and K. Schulze-Osthoff Many cuts to ruin: a comprehensive update of caspase substrates Cell Death Differ 10 2003 76 100
20. J.M. Cline, G. Söderqvist, T.C. Register, J.K. Williams, M.R. Adams, and B. Von Schoultz Assessment of hormonally active agents in the reproductive tract of female nonhuman primates Toxicol Pathol 29 2001 84 90
21. J.M. Cline, T.C. Register, and T.B. Clarkson Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys Menopause 9 2002 422 429
22. M.R. Adams, T.C. Register, D.L. Golden, J.D. Wagner, and J.K. Williams Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis Arterioscler Thromb Vasc Biol 17 1997 217 221
23. D. Wynford-Thomas P53 in tumour pathology: can we trust immunocytochemistry? J Pathol 166 1992 329 330
24. V.K. Moudgil, S. Dinda, N. Khattree, S. Jhanwar, P. Alban, and C. Hurd Hormonal regulation of tumor suppressor proteins in breast cancer cells J Steroid Biochem Mol Biol 76 2001 105 117
25. J.R. Pasqualini, and G.S. Chetrite Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications J Steroid Biochem Mol Biol 69 1999 287 292
26. A. Gompel, M. Chaouat, D. Jacob, J.Y. Perrot, H.J. Kloosterboer, and W. Rostene In vitro studies of tibolone in breast cells Fertil Steril 78 2002 351 359
27. J. Tsihlias, L. Kapusta, and J. Slingerland The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer Annu Rev Med 50 1999 401 423